anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Players in this group will be asked to include the food groups in the MIND diet in their diet in accordance with their consumption frequency. As a result of the interviews with the coaches and experienced athletes, it was learned that the majority of the athletes did not consume the foods such as wine, berries, and fish included in the MIND diet template. Therefore, these foods, which are the main components of the MIND diet, will be provided by the researcher/project in accordance with the recommended frequencies. However, since wine consumption is not frequently preferred in our country due to religious and socio-cultural reasons, ''hardaliye'', a fermented grape juice (100 mL/day), which is easy to consume and has similar nutritional values to wine (resveratrol and ORAC), will be provided. Berries will be supplied in 2 portions/week, and fish (tons) in 1 portion/week.
Laparoscopic inguinal hernia surgery is a common procedure and pain is a common postoperative complication. Guidelines for mesh fixation vary, with no clear rule. Mesh fixation may not be necessary in total extraperitoneal approach (TEP), but more research is needed for transabdominal preperitoneal approach (TAPP). This study was conducted comparing mesh fixation methods using a suture passer and tacker, aiming to reduce pain and operation time. We used the FUÇA method for mesh fixation in TAPP. The patients were divided into two groups: Group I underwent classical tacker method while Group II used the FUÇA method. There were 52 patients in Group I and 51 patients in Group II. Polypropylene mesh was used in both groups. The surgeries were performed by four experienced surgeons. We analyzed retrospective data including age, gender, BMI, surgical approach, procedure duration, defect size, recurrence status, postoperative pain, hernia type, and complications. Pain was assessed using VAS score and McGill pain index. Recurrence was evaluated by a different surgeon. A total of 103 patients were included: 52 in Group I and 51 in Group II. Both groups had a similar median age (47 years in Group I, 45 years in Group II) and predominantly male participants (92.3% in Group I, 92.2% in Group II). Most patients had indirect inguinal hernia (77.7%) while the rest had direct inguinal hernia (22.3%). There were no significant differences in BMI or hernia type between the groups. The defect size measured by ultrasound was similar in both groups. Group I had higher VAS pain scores on postoperative day 1, at month 1, and at month 3 compared to Group II, but the difference vanished at the 12-month mark. The McGill Pain Index showed similar results. Recurrence was observed in one patient in each group. Complications occurred in 11 patients during the follow-up period, with similar rates between the groups. The mean surgical procedure time of Group 2 was significantly shorter than that of Group 1 (49.36 m vs 43.43 m, p = 0.009). FUÇA method is a technique that can be used safely in the TAPP procedure as it reduces postoperative pain and shortens the operation time.
Patients receive ranolazine PO BID for 1 day. Patients undergo FDG-PET/CT scan at baseline and after ranolazine treatment. Patients may then undergo robotic or open radical prostatectomy.
The invention relates to a linear implant identification method. The method comprises the following steps: acquiring a first projection length of the implant in a first direction and a second projection length in a second direction; calculating the length of the hypotenuse by taking the first projection length and the second projection length as the right-angle sides of the right-angle triangle; identifying whether the implant is a linear implant based on the area of the implant and the length of the hypotenuse. The invention also relates to a linear implant identification device and a storage medium. The method, the device and the storage medium calculate the length of the hypotenuse by taking the first projection length and the second projection length as the right-angle side of a right-angle triangle. The area of the implant is a determined value. The width of the implant can be simulated by the area and the length of the bevel edge. Thereby determining whether the implant is a linear implant. In this way, it is possible to identify whether the implant in the image is a linear implant accurately and quickly.
Culturally Adapted Motivational Interview. Participants will receive a single session, 75 minute addiction counseling discussion that focuses on the causes of addictive behavior. They will receive a CAMI booster session at 2 months and standard care in a primary care setting.
The invention relates to a method for long-term preservation of antibiotics at room temperature. The method includes: mixing an antibiotic solution into a silk protein solution, then putting the mixture into a mold to prepare a silk film so as to preserve antibiotics in the silk film. The prepared silk film can keep the drug properties of antibiotics at room temperature, so that the vitality of the antibiotics can keep stable for a long time (in 6 months). Compared with the prior art, silk protein contains a nanoscale pocket, and can accommodate and protect biological compounds. Therefore, the silk protein involved in the invention can be utilized to accommodate and protect antibiotics so as to maintain the effectiveness of antibiotics. The antibiotics wrapped by silk protein can keep stability for up to half a year at room temperature, even for one month at 60DEG C, and still can maintain its efficacy.
Each year 98% of US newborns receive screening (NBS) of dried blood spots (DBS) for at least 35 Recommended Uniform Screening Panel (RUSP) genetic disorders for diagnosis and treatment at/before onset of symptoms. About 6,600 true positive infants are identified per year. NBS is well-accepted and has proven clinical utility. Between 2010 and 2022, however, while many new therapeutic interventions for childhood genetic diseases showed clinical utility and/or were approved by the Food and Drug Administration (FDA), only 6 disorders were added to the RUSP. As a result, \~700 childhood genetic diseases have effective treatments but are not yet screened by NBS, and affected children experience delayed diagnosis and treatment, and poor outcomes. To solve this problem the investigators are developing BeginNGS - NBS by genome sequencing (GS) of DBS for, ultimately, \~700 severe, childhood genetic diseases with effective therapeutic interventions. BeginNGS is adaptive: genetic disorders are added (or removed) as evidence emerges that early treatment improves (or does not improve) outcomes. BeginNGS version 1 (v1, 388 genetic disorders) had good sensitivity (88.8%) and false positive rate (0.27%) in a retrospective study of 458,000 subjects. An exploratory prospective clinical trial comparing BeginNGS v2 (with 409 disorders) and rapid diagnostic genome sequencing (RDGS) identified reportable findings in 24 (34%) of 71 acutely ill newborns who were not suspected of having a genetic disease. Only 2 of those disorders were detected by standard NBS. The investigators propose a single group, multicenter, adaptive clinical trial to compare utility, acceptability, feasibility, and cost effectiveness of BeginNGS (experimental intervention) with standard NBS (control) in a minimum of 10,000 neonates (aged \<28 days, maximum of 100,000). The primary objective of the trial is to generate evidence to support broad implementation of BeginNGS. An adaptive design was chosen rather than a traditional, fixed design to allow accumulating results to make the trial more efficient, informative, and ethical by addition or removal of BeginNGS disorders and genetic variants, population enrichment (for minority racial, ethnic, and ancestral groups), and sample size re-estimation. Adaptive design will also facilitate meta-analysis with other clinical trials of NBS-by-GS, providing greater power to test utility in ultra-rare genetic diseases. NBS-by-GS has the potential to transform the way childhood genetic diseases are diagnosed and treatments started. Preliminary data suggest that national adoption of BeginNGS in all births has the potential to improve outcomes of \>50,000 US children per year.
Extraction devices and related methods are disclosed. Extraction devices disclosed may include a hopper, a piston, and an evaporation chamber. The hopper may be filled with a plant material and a solvent. The piston may be removably housed within the hopper so as to form a hermetic seal with the hopper. Once a solvent and extract mixture is formed within the hopper, a valve in the bottom of the hopper may be opened to allow the solvent and extract mixture to flow into the evaporation chamber via gravity. The remaining plant material may be compressed by the piston to remove any remaining solvent and extract mixture. The solvent may be evaporated in the evaporation chamber leaving a purified plant extract. Various types of plant materials may be used within the hopper. Various types of solvents may be used as well, including heptane and hexane.
Application of testosterone in transdermal gel during the 2 cycles prior to initiation of controlled ovarian stimulation and until the onset of second menstruation (approximately 56 days). The COS begins the day after the last testosterone application.
PCLR A 0.5 cm stab wound is made at lateral aspect of first MTPJ. A No. 15 beaver blade is advanced into the lateral side of MTPJ with a quarter of the blade inside the joint and verified with fluoroscope. The blade is turned laterally to face the adductor hallucis tendon. The adductor tendon is divided with lateral movement of the blade and varus manipulation of proximal phalanx. A click is heard as adequate release of adductor hallucis tendon. Same intraoperative stress test is performed and recorded under fluoroscope to confirm correction.
Subjects in the first cohort will receive 150 mg and 300 mg ascending doses of naringenin and subjects in the second cohort will receive 600 mg and 900 mg ascending doses of naringenin. Each cohort will also have a placebo group.
Contingency management (CM) treatments are efficacious in reducing substance use. A relatively new approach, called prize-based CM, which uses prizes to reinforce substance abstinence, is effective in decreasing certain types of substance use, but its efficacy has not been evaluated in the treatment of cigarette smoking. One purpose of the current study is to assess the efficacy of a prize reinforcement intervention for reducing cigarette smoking. A second purpose is to test the differential efficacy of two schedules of reinforcement, using cigarette smoking as an exemplar. We will randomly assign 110 patients to one of three conditions: 1) Standard treatment; 2) Traditional prize reinforcement; or 3) Early-treatment enhanced prize reinforcement. Patients in each condition will receive counseling for their smoking based on current standard of care guidelines. All patients will participate in a one-week baseline period, followed by a four-week intervention. Throughout both phases, each patient will meet with a research assistant twice daily to provide carbon monoxide (CO) samples. Patients in the prize reinforcement conditions will earn the chance to win prizes when they provide negative CO samples (i.e., \< 6ppm). They will also earn bonus draws if they provide negative cotinine samples (i.e., \<100ng/ml) after weekends. Patients in the Traditional CM condition will have at least a 50% chance of winning a prize for each negative sample with escalating chances for successive negative samples. Patients in the Enhanced condition will have the opportunity to earn the same overall number of draws and magnitude of reinforcement, but the schedule of reinforcement will differ. For the first week of the CM phase, these patients will have a 100% chance of winning prizes, but in the latter 3 weeks, overall probability of reinforcement will be decreased to 34%. Patients will also undergo 2- and 6-month follow-up assessments. Primary outcome measures will be longest duration of continuous abstinence and mean number of days of abstinence. We predict that the prize reinforcement will reduce cigarette smoking to a greater extent than standard treatment. We also predict that the Enhanced CM condition will lead to greater reductions in cigarette smoking relative to the Traditional CM condition, and that these changes may result in longer sustained abstinence from smoking throughout the study period.
Patients receive vemurafenib PO BID on days 1-14, cetuximab IV over 90 minutes, and irinotecan hydrochloride IV over 90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Objective:To investigate the long-term effect of partial tonsillectomy in children with tonsil hypertrophy. Methods:A total of 146 children with obstructive sleep apnea(OSA) who received surgical treatment for tonsil hyperplasia from January 2010 to January 2013 were selected and divided into the observation group(n=69) and the control group(n=77). The observation group was received tonsillotomy(TT), and the control group was received total tonsillectomy(TE). Parental satisfaction and OSA quality of life questionnaire for children(OSA-18) were surveyed. Residual tonsil size was measured, and polysomnography(PSG) was monitored after 10 years. HE and immunohistochemical analysis were performed on tonsil tissues of one patient who performed a second operation after TT in 2017 year. Results:The results of questionnaire survey showed that the symptoms of respiratory obstruction were significantly improved in both groups, and the satisfaction of TT group was higher than that in the TE group. No increase in the number of respiratory tract infections was observed in all patients. In the TT group, nine cases(13.04%) had tonsil hyperplasia toⅡ°, and the remaining patients had tonsil hyperplasia to Ⅰ°. In addition, one case hadtonsil suppurative infection at the 14th month after surgery, and no recurrence or reoperation was found after treatment. There were seven cases in the TT group and eight cases in the TE group with occasional snoring and mouth breathing after surgery, but the PSG examination of the patients did not meet the diagnosis of OSA. The main causes were obesity and allergic rhinitis. Compared with the first operation, the cicatricial obstruction and infection of tonsil tissue in the second operation were not significantly changed, and the immunohistochemical results also demonstrated that the expression of CD20 was not changed, and the expression of CD3 was decreased. Conclusion:Both TT and TE can effectively improve the symptoms of OSA obstruction in children. TT has less trauma, less postoperative pain, faster recovery and lower rate of hyperplasia, which can be used as one of the main methods for the treatment of tonsil hypertrophy in children.
Natural killer (NK) cells are the predominant lymphocyte population in the liver. At the onset of non-alcoholic steatohepatitis (NASH), an accumulation of activated NK cells is observed in the liver in parallel with inflammatory monocyte recruitment and an increased systemic inflammation. Using in vivo and in vitro experiments, we unveil a specific stimulation of NK cell-poiesis during NASH by medullary monocytes that trans-present interleukin-15 (IL-15) and secrete osteopontin, a biomarker for patients with NASH. This cellular dialogue leads to increased survival and maturation of NK precursors that are recruited to the liver, where they dampen the inflammatory monocyte infiltration. The increase in the production of both osteopontin and the IL-15/IL-15Rα complex by bone marrow monocytes is induced by endotoxemia. We propose a tripartite gut-liver-bone marrow axis regulating the immune population dynamics and effector functions during liver inflammation.
PURPOSE: Low anterior resection syndrome (LARS) causes devastating symptoms and impairs the quality of life (QOL). This study investigated the incidence and risk factors of LARS and their association with the QOL in patients with lower rectal tumors.
METHODS: Patients who underwent anus-preserving surgery for lower rectal tumors between 2014 and 2019 and who had anal defecation between 2020 and 2021 were surveyed. The LARS score measured severity, and the QOL was evaluated using the Japanese version of the Fecal Incontinence Quality-of-Life Scale (JFIQL). The primary endpoint was the incidence of Major LARS, and the secondary endpoints were risk factors and association with the JFIQL.
RESULTS: Of 107 eligible patients, 82 (76.6%) completed the LARS survey. The incidence of Major LARS was 48%. Independent risk factors included neoadjuvant chemoradiotherapy (CRT) and a short interval (< 24 months after surgery; odds ratio, 4.6; 95% confidence interval: 1.1-19, both). The LARS score was moderately correlated with the JFIQL generic score (correlation coefficient: - 0.54). The JFIQL scores were significantly worse in the Minor and Major LARS groups than in the No LARS group.
CONCLUSIONS: Major LARS was found in 48% of lower rectal tumors, and independent risk factors include neoadjuvant CRT and a short interval. The QOL was significantly impaired in patients with both Minor and Major LARS.
The investigators will review video-recordings of three randomized controlled trials (NCT01535326, 01699399, and 01894191) comparing air insufflation, water immersion and water exchange. These studies were conducted at Buddhist Dalin Tzu Chi Hospital. Permission will be obtained from the local Institutional Review Board (IRB) to review, analyze and report de-identified findings.

Two experienced endoscopists (YHH and CWT) performed all the recorded colonoscopies. Recordings will be selected for review if they are complete examinations; include clear identification of the appendiceal orifice and/or the ileocecal valve, indicating arrival at the cecum; available in the appropriate format for video editing; and contain no patient or endoscopist identifiers. Patients with incomplete recordings and a history of bowel resection will be excluded from analysis. The included video recordings will be edited to remove the insertion phase to blind the study reviewer to the insertion techniques. One blinded reviewer uninvolved in the performance of the colonoscopies will be in charge of evaluating the selected videos, using the criteria described by Yung et al
PROBLEM TO BE SOLVED: To provide techniques for assisting in finding motivation required to maintain an exercise program.SOLUTION: An athletic monitoring device includes or is coupled with multiple types of movement sensors, and switches between the sensors or uses both sensors depending on various factors including a type of workout. Workouts are also tagged with various parameters including mood, weather, terrain, athletic equipment used and the like. The parameters are automatically determined on the basis of a location. User workouts and accomplishments are also celebrated through messages from celebrities, family, friends and other users. The messages are triggered by various conditions. Coaching is also provided to the user to help improve workouts and overall athletic performance. Running routes are also automatically tracked, stored and shared.
PROBLEM TO BE SOLVED: To prepare the subject cosmetic good in portability and convenient to use, reduced in cracking tendency in products and volatility, containing specific wax ester(s) and amphoteric surfactant(s), etc. SOLUTION: This oil-in-water-type solid cosmetic comprises (A) 0.1-10wt.% of at least one kind of wax ester composed of segment derived from an 18-34C higher fatty acid (e.g. 18C octadecanoic acid) and segment derived from an 18-44C higher aliphatic alcohol (e.g. 18C stearyl alcohol), (B) 0.5-10wt.% of at least one kind of amphoteric surfactant, (C) 0.001-40wt.% of at least one kind of ingredient selected from silicone oils, ester oils, respective fatty acid esters of higher alcohols, ethylene glycol and glycerol, and water-soluble polymers, and (D) 0-10wt.% of a 6-34C higher fatty acid (e.g. 6C hexanoic acid) as an optional ingredient. These ingredients are homogeneously admixed with one another or emulsified and prepared into a form of foundation, eyeshadow, lipstick, etc.
AIM: To explore whether ultrasound (US) can be employed to identify the underlying characteristics associated with pain in patients with podagra by evaluating the relationship between ultrasound findings and clinical pain.
MATERIAL AND METHODS: Patients with podagra were recruited and grouped into a pain group (G1, 82 patients) and a non pain group (G2, 123 patients). US features were collected and compared. US data were analyzed by binary logistic regression analysis and ROC analysis. Interobserver reliability was assessed, too.
RESULTS: A total of 205 patients (196 male and 9 female) were enrolled in this study. In multivariate analysis, the thickness of the synovium (OR=1.928, CI=1.074-3.463), CD (color Doppler) signal of the synovium (OR=1.458, CI=1.011-2.103), and CD signal of the tophi (OR=1.576, CI=1.142-2.177) were identified as risk factors for clinical pain. Areas under the ROC curves (AUC) were 0.713, 0.686 and 0.641 for the three indicators, respectively. The best cutoff points were 1 mm for the thickness of the synovium, grade 1 for the CD signal of the synovium and grade 2 for the CD signal of the tophi.
CONCLUSIONS: Ultrasound can provide valuable information for determining underlying features associated with pain in patients with podagra.
The strength training (ST) program incorporates single-leg exercises for balance training and training with resistance bands and body weight. During the ST, participants will be asked to synchronize their concentric and eccentric muscle contractions in time with the tempo of BMS playlists at a specific music tempo. For aerobic exercise (AE), participants will be instructed to walk at moderate intensity with duration increasing up to an ultimate goal of 150 min/week. Participants will be trained to walk in synchrony with the beats. Participants will receive individualized music playlists to match individual walking cadence and music preference.
This project will be launched after the first introduction of Virtue® Male Sling in Europe. This study is a multicenter prospective, non-interventional (i.e. naturalistic) post-marketing clinical follow up of men with urinary incontinence implanted with Virtue® Male Sling System by urologists who are experienced in the device. The patient will be followed for 12 months in routine real world clinical practice except for administration of subject questionnaire(s). Routine visits will be performed approximately at baseline (preoperative and implantation period), between 1 and 3 months (immediate post-operative period) and 12 months. Then questionnaires will be mailed annually during 2 additional years.
Place the adhesive side of LYLLANA on a clean, dry area on the lower abdomen (below the umbilicus) or buttocks. Do not apply LYLLANA to the breasts. 

Replace LYLLANA twice weekly (every 3 to 4 days). 

Rotate the sites of application, with an interval of at least 1 week allowed between applications to a particular site. 

Select an area for application that is not oily, damaged, or irritated. Avoid the waistline, since tight clothing may rub the system off. Apply the system immediately after opening the pouch and removing the protective liner. Press the system firmly in place with the palm of the hand for about 10 seconds, making sure there is good contact with the skin, especially around the edges. In the event that a system falls off, reapply the same system or apply a new system to another location. In either case, continue the original treatment schedule. If a woman has forgotten to apply LYLLANA, have her apply a new system as soon as possible. Apply the new system on the original treatment schedule. The interruption of treatment in women taking LYLLANA might increase the likelihood of breakthrough bleeding, spotting and recurrence of symptoms.